The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Depreciation | - | - | - | 1,036 |
| Net loss | -49,013 | -50,216 | -40,666 | -76,913 |
| Depreciation | 537 | 525 | 559 | 1,000 |
| Stock-based compensation | 8,715 | 9,875 | 8,085 | 16,792 |
| Accretion of discount on marketable securities, net | 1,013 | 1,483 | 2,056 | 4,126 |
| Amortization of right-of-use asset | 53 | 50 | 47 | 85 |
| Prepaid expenses and other assets | -3,045 | 2,715 | 1,298 | 3,950 |
| Accounts payable | 1,446 | -303 | -2,132 | 2,707 |
| Accrued compensation | -6,752 | 4,432 | 2,362 | -4,420 |
| Accrued other expenses and other liabilities | 635 | 1,436 | 548 | -1,293 |
| Lease liability | -196 | -193 | -189 | -366 |
| Net cash used in operating activities | -42,543 | -38,592 | -34,776 | -70,448 |
| Maturities of marketable securities | - | - | - | 229,118 |
| Purchases of marketable securities | 110,152 | 74,285 | 66,999 | 385,942 |
| Sales of marketable securities | 3,966 | 15,932 | 12,802 | 38,650 |
| Maturities of marketable securities | 108,879 | 108,188 | 319,120 | - |
| Purchases of property and equipment | 260 | 73 | 89 | 94 |
| Net cash provided by investing activities | 2,433 | 49,762 | 35,716 | -118,268 |
| Proceeds from employee stock purchase plan | - | 325 | 0 | 598 |
| Proceeds from issuance of common stock, net of offering costs | - | 0 | 0 | 187,362 |
| Exercise of stock options | 12,173 | 3,650 | 1,659 | 2,494 |
| Net cash provided by financing activities | 12,173 | 3,975 | 1,659 | 190,454 |
| Net change in cash and cash equivalents | -27,937 | 15,145 | 2,599 | 1,738 |
| Cash and cash equivalents at beginning of period | 61,148 | 46,003 | 41,666 | - |
| Cash and cash equivalents at end of period | 33,211 | 61,148 | 46,003 | - |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)